Twist Bioscience Corp

CRISPR Therapeutics

Recursion Pharmaceuticals

CareDx

Adaptive Biotechnologies

Veracyte

Ionis Pharma

Nurix Therapeutics, Inc

Intellia Therapeutics

10X Genomics

ARK Genomic Revolution Multi-Sector ETF

ARKG is an actively managed fund that targets companies involved in the genomics industry.

One of the primary objectives of genomics is to make strides in areas where traditional healthcare procedures and techniques have failed or aren't generating enough in the way of advancements and improving patient outcomes. Accessing the cutting edge traits offered by genomics is one of the reasons why many investors embrace the ARK Genomic Revolution [.

Genomics Advancements Could Aid Breast Cancer Prevention

ARK Innovation ETF

A couple of ARK Invest exchange-traded funds run by ETF star Cathie Wood bought over 850,000 shares of Pacific Biosciences of California Inc.

Cathie Wood's ARK Invest Buys Over 850,000 Shares of Pacific Bio

ARK Fintech Innovation ETF

ARK Industrial Innovation ETF

ARK Web x.0 ETF

Global X Robotics & Artificial Intelligence ETF

Amplify Online Retail ETF

Global X Lithium & Battery Tech ETF

Amplify Thematic All-Stars ETF

Global X U.S. Infrastructure Development ETF

The Ark Invest founder's proven ability to create alpha with thematic investing bolsters the outlook for the whole space, says Amplify CEO Christian Magoon.

Cathie Wood's mission is bullish for thematic ETF investing, Amplify CEO says

The coronavirus pandemic that began in 2020 and is persisting today has led many investors to hold poor market expectations. But maybe they shouldn't be so pessimistic.

Q2 Growth 'Nothing Short Of Virtuous': Economist

Kodiak Sciences Inc

Regeneron Pharmaceuticals

This mid-cap growth stock could be a long-term winner.

Is This Mid-Cap Biotech Stock a Buy Now?

As an actively managed exchange traded fund, the ARK Genomic Revolution Multi-Sector Fund (CBOE: ARKG) can more nimbly move into new healthcare frontiers than rival index-based products. Synthetic biology could be a new example of ARKG's long-running adaptability.

Unpacking the Potential of the Synthetic Biology Space

ARK Space Exploration & Innovation ETF

ARK Invest had some of the hottest exchange-traded funds (ETFs) of 2020, with massive gains across the board.

ARK Invest's Weak Q2 Could Be Setting Up for Something Big

With mergers and acquisitions activity yet to heat up, healthcare stocks are lagging the broader market to this point in 2021. The ARK Genomic Revolution Multi-Sector Fund (CBOE: ARKG) hasn't been immune to that trend, but the ARK fund also stands out as one of the exchange traded funds in this category that could rapidly [.

How Healthcare ETFs Can Get Their Swagger Back

It's often said that disruptive technologies frequently intersect with each other. For example, cloud computing and the Internet of Things (IoT) are frequently linked to advancements in cybersecurity.

The ARKG ETF and the Intersection of All Things Tech

Cathie Wood's genomics ETF is making big bets on the "Genomic Age."

Where Will ARK Genomic Revolution ETF Be in 5 Years?

VanEck Vectors Biotech ETF

Principal Healthcare Innovators Index ETF

Loncar Cancer Immunotherapy ETF

iShares Nasdaq Biotechnology ETF

iShares Genomics Immunology and Healthcare ETF

Invesco Dynamic Biotechnology & Genome ETF

ALPS Medical Breakthroughs ETF

SPDR S&P Biotech ETF

Biotechnology is a dynamic but often volatile industry. These biotech ETFs provide a lower-risk way to invest in the space.

9 Best Biotech ETFs to Play High-Octane Trends

COVID-19 has only revealed a small glimpse of the possibilities offered by genomics, a field which is leading us towards predictive and personalized health care. However, ARKG goes beyond just genomic sequencing and editing.

ARKG: More Than Just Genomes

The ARK Genomic Revolution Multi-Sector Fund (CBOE: ARKG) closed June on a strong note. It's not difficult to explain why.

Play the New Era of Gene Editing with the ARKG ETF

Global X Genomics & Biotechnology ETF

The genomic-editing space has come under the spotlight with the release of encouraging data from a study assessing an in vivo CRISPR-based gene editing therapy candidate, NTLA-2001.

Genomics ETFs Surge on a Major Breakthrough in CRISPR Study

Shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA) surged Monday after the firm and another company known as Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) over the weekend announced positive results from an ongoing Phase I clinical trial for an in vivo genome editing therapy known as NTLA-2001. The ARK Genomic Revolution Multi-Sector Fund (CBOE: ARKG) was one of [.

New Gene Editing Trial Results Bump the ARKG ETF

Invesco NASDAQ Next Gen 100 ETF

Invesco QQQ

The Fed's change in outlook might point to stormier waters ahead for the rebounding ARK suite and other tech-heavy funds.

ARK ETFs Grind Higher Amid Chop

Last week, the Food & Drug Administration (FDA) approved Biogen's Aducanumab, a potentially revolutionary Alzheimer's treatment. While the approval represents one of the first landmarks in the quest to improve outcomes for Alzheimer's patients, the news wasn't without controversy.

Biogen Alzheimer's Approval Could Signal FDA's Flexibility

Biogen

Clover Health Investments

First Trust NYSE Arca Biotechnology Index Fund

Orphazyme A/S

Investors may want to tap the bullishness in the sector with the best biotech ETFs of last week.

Top-Performing Biotech ETFs of Last Week

Direxion Daily S&P Biotech Bull 3X Shares

ARK Active ETFs are worth the management fee. Structured Lookback is introduced.

ARK: Cathie Wood And The Exquisite Art Of Tail Gunning

Which biotech/genomics ETF is the better play?

ETF Battles: ARKG Vs GNOM

Two big biotech stocks and one smaller life sciences stock especially stand out.

The Best Stocks to Buy in Cathie Wood's ARK Genomic Revolution ETF

The COVID-19 pandemic accelerated adoption of an array of disruptive growth technologies, including e-commerce, fintech, and more. Healthcare innovation is part of that trend, and the ARK Genomic Revolution Multi-Sector Fund (CBOE: ARKG) is an exchange traded fund for investors to consider as the pandemic compels healthcare professionals to explore new concepts in genetic testing.

Pandemic Opening the Door for Widespread Genetic Testing

For growth investors seeking disruptive exposure in the healthcare sector, genomics is often a favored destination. The industry pushes an array of advances that can improve diagnoses, disease screening and treatment, and patient outcomes.

A Base Hit: How Base Editing Is Changing Genomics

First Trust US Equity Opportunities ETF

Renaissance IPO ETF

Defiance Next Gen SPAC Derived ETF

SPAC and New Issue ETF

From 'ARKK' to 'SPAK' to 'IPO,' these once-hot ETFs have noticeably cooled.

High Flying ETFs Reverse Course

ARK investors were happy for the most part, despite the broad markets sliding lower at the end of Tuesday's session.

News for ARK Genomic Revolution Multi-Sector ETF ETF (ARKG)